UNMC commences clinical trial of remdesivir for treating COVID-19
Category: #health  By Pankaj Singh  Date: 2020-02-27
  • share
  • Twitter
  • Facebook
  • LinkedIn

UNMC commences clinical trial of remdesivir for treating COVID-19

A controlled, randomized clinical trial to evaluate the efficacy and safety of the investigational antiviral, remdesivir, in COVID-19 patients has reportedly commenced at the University of Nebraska Medical Center (UNMC) in Omaha.

According to sources, this clinical trial is being sponsored by NIAID (National Institute of Allergy and Infectious Diseases), a division of the National Institutes of Health (NIH).

It is the first clinical study in the U.S. to determine an experimental therapy for COVID-19. The first participant to register in the clinical trial is an American who was brought to the UNMC campus after being quarantined on the Diamond Princess cruise ship that berthed in Yokohama, Japan. The person agreed to participate in the clinical study.

Presently, there are no particular treatments approved by the U.S. FDA to treat people with COVID-19. On Feb. 24, the WHO ( World Health Organization ) had recorded 77,262 confirmed COVID-19 cases and 2,595 deaths in China and 2,069 confirmed cases and 23 deaths in 29 other nations.

As per CDC (Centers for Disease Control and Prevention), there have been fourteen confirmed cases recorded in the U.S. and further 39 cases among persons deported to the U.S.

Clinical studies of remdesivir are also progressing in China. NIAID developed the present study taking those designs into account and in line with consultations convened by the WHO on the advancement of clinical trials for COVID-19 patients.

Anthony S. Fauci, M.D., the United States Coronavirus Task Force member and Director of NIAID, said that there is an urgent need for an effective and safe treatment for COVID-19. Fauci added that though remdesivir has been administered to a few COVID-19 patients, they do not possess the data indicating it could enhance clinical results.

A placebo-controlled, randomized clinical trial is the gold standard for defining experimental treatment benefit in coronavirus patients.

Source Link - https://www.nih.gov/news-events/news-releases/nih-clinical-trial-remdesivir-treat-covid-19-begins 



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

Anova Enterprises expands AnovaOS™ to boost clinical development
Anova Enterprises expands AnovaOS™ to boost clinical development
By Pankaj Singh

The U.S-based Anova Enterprises, Inc. (Anova) has reportedly expanded the AnovaOS™ technology platform in order to boost the development of promising novel treatments. The platform brings pharmaceutical companies...

Serum Institute to Resume Oxford COVID-19 Vaccine’s Trail in India
Serum Institute to Resume Oxford COVID-19 Vaccine’s Trail in India
By Pankaj Singh

India’s Drugs Controller General (DCGI) has approved Pune-based Serum Institute of India (SII) to restart the clinical trial of the Oxford/AstraZeneca COVID-19 vaccine in India.

Everest Medicines Announces Cefepime-Taniborbactam Phase 1 Results

Everest Medicines Announces Cefepime-Taniborbactam Phase 1 Results
By Pankaj Singh

Everest Medicines announced the top-line results from the Phase 1 clinical trial of Taniborbactam with cefepime for treating infections caused by multi-drug resistant pathogens in China. Everest Medicines is a biopharm...